Objectives. In this study a new method for asthma outcome prediction, which is based on Principal Component Analysis and Least Square Support Vector Machine Classifier, is presented. Most of the asthma cases appear during the first years of life. Thus, the early identification of young children being at high risk of developing persistent symptoms of the disease throughout childhood is an important public health priority. Methods. The proposed intelligent system consists of three stages. At the first stage, Principal Component Analysis is used for feature extraction and dimension reduction. At the second stage, the pattern classification is achieved by using Least Square Support Vector Machine Classifier. Finally, at the third stage the performance evaluation of the system is estimated by using classification accuracy and 10-fold cross-validation. Results. The proposed prediction system can be used in asthma outcome prediction with 95.54 % success as shown in the experimental results. Conclusions. This study indicates that the proposed system is a potentially useful decision support tool for predicting asthma outcome and that some risk factors enhance its predictive ability.

The long-term solution to the asthma epidemic is believed to be prevention and not treatment of the established disease. Most cases of asthma begin during the first years of life; thus the early determination of which young children will have asthma later in their life counts as an important priority. Artificial neural networks (ANN) have been already utilized in medicine in order to improve the performance of the clinical decision-making tools. In this study, a new computational intelligence technique for the prediction of persistent asthma in children is presented. By employing partial least square regression, 9 out of 48 prognostic factors correlated to the persistent asthma have been chosen. Multilayer perceptron and probabilistic neural networks topologies have been investigated in order to obtain the best prediction accuracy. Based on the results, it is shown that the proposed system is able to predict the asthma outcome with a success of 96.77%. The ANN, with which these high rates of reliability were obtained, will help the doctors to identify which of the young patients are at a high risk of asthma disease progression. Moreover, this may lead to better treatment opportunities and hopefully better disease outcomes in adulthood.

No abstract

Cancer is a leading cause of death worldwide and the prognostic evaluation of cancer patients is of great importance in medical care. The use of artificial neural networks in prediction problems is well established in human medical literature. The aim of the current study was to assess the prognostic value of a series of clinical and molecular variables with the addition of γ-H2AX—a new DNA damage response marker—for the prediction of prognosis in patients with early operable non-small cell lung cancer by comparing the γ-H2AX-based artificial network prediction model with the corresponding LR one. Two prognostic models of 96 patients with 27 input variables were constructed by using the parameter-increasing method in order to compare the predictive accuracy of neural network and logistic regression models. The quality of the models was evaluated by an independent validation data set of 11 patients. Neural networks outperformed logistic regression in predicting the patient's outcome according to the experimental results. To assess the importance of the two factors p53 and γ-H2AX, models without these two variables were also constructed. JR and accuracy of these models were lower than those of the models using all input variables, suggesting that these biological markers are very important for optimal performance of the models. This study indicates that neural networks may represent a potentially more useful decision support tool than conventional statistical methods for predicting the outcome of patients with non-small cell lung cancer and that some molecular markers, such as γ-H2AX, enhance their predictive ability.

No abstract